← All trials
NCT00198822
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2001
- Primary completion
- Jan 1, 2007
- Completion date
- Mar 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 59666
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Johns Hopkins UniversityLead sponsor
- Johns Hopkins UniversityOverall official - principal investigator
- Johns Hopkins UniversityStudy director
- Bill and Melinda Gates FoundationCollaborator
- Canadian International Development AgencyCollaborator
- The Sight and Life Research InstituteCollaborator
- United States Agency for International DevelopmentCollaborator
- Johns Hopkins UniversityReponsible party - principal investigator
- Access Business Group, LLCCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.